Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Investment
BeiGene to codevelop BioAtla’s CTLA4 antibody
by Ryan Cross
April 12, 2019
| A version of this story appeared in
Volume 97, Issue 15
The Chinese cancer drug company BeiGene is partnering with San Diego–based BioAtla to develop a less-toxic version of the CTLA4 antibodies used in cancer immunotherapy. The adoption of CTLA4 antibodies, a kind of checkpoint inhibitor, has been impeded due to their toxicity outside tumors, especially compared with the PD-1 checkpoint inhibitor class. BioAtla has a version that it says is activated only in the tumor microenvironment. BeiGene will pay BioAtla $20 million up front and up to $249 million more in future payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X